<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Terapevticheskii arkhiv</journal-id><journal-title-group><journal-title xml:lang="en">Terapevticheskii arkhiv</journal-title><trans-title-group xml:lang="ru"><trans-title>Терапевтический архив</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0040-3660</issn><issn publication-format="electronic">2309-5342</issn><publisher><publisher-name xml:lang="en">LLC Obyedinennaya Redaktsiya</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">32076</article-id><article-id pub-id-type="doi">10.17116/terarkh201688965-70</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Editorial article</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Передовая статья</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Role of vascular remodeling markers in the development of osteoporosis in idiopathic pulmonary arterial hypertension</article-title><trans-title-group xml:lang="ru"><trans-title>Роль маркеров ремоделирования сосудов в формировании остеопороза при идиопатической легочной артериальной гипертонии</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Nevzorova</surname><given-names>V A</given-names></name><name xml:lang="ru"><surname>Невзорова</surname><given-names>В А</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kochetkova</surname><given-names>E A</given-names></name><name xml:lang="ru"><surname>Кочеткова</surname><given-names>Е А</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Ugay</surname><given-names>L G</given-names></name><name xml:lang="ru"><surname>Угай</surname><given-names>Л Г</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Maistrovskaya</surname><given-names>Yu V</given-names></name><name xml:lang="ru"><surname>Майстровская</surname><given-names>Ю В</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Khludeeva</surname><given-names>E A</given-names></name><name xml:lang="ru"><surname>Хлудеева</surname><given-names>Е А</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en"></institution></aff><aff><institution xml:lang="ru">Тихоокеанский государственный медицинский университет Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2016-09-15" publication-format="electronic"><day>15</day><month>09</month><year>2016</year></pub-date><volume>88</volume><issue>9</issue><issue-title xml:lang="en">VOL 88, NO9 ()</issue-title><issue-title xml:lang="ru">ТОМ 88, №9 (2016)</issue-title><fpage>65</fpage><lpage>70</lpage><history><date date-type="received" iso-8601-date="2020-04-10"><day>10</day><month>04</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2016, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2016, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2016</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://ter-arkhiv.ru/0040-3660/article/view/32076">https://ter-arkhiv.ru/0040-3660/article/view/32076</self-uri><abstract xml:lang="en"><p>Aim. To define the role of circulating biomarkers for the metabolism of collagen and intercellular substance and vascular remodeling in the development of osteoporosis (OP) in idiopathic pulmonary arterial hypertension (IPAH). Materials and methods. Functional hemodynamic parameters, bone mineral density (BMD) in the lumbar spine and femoral neck and the serum levels of matrix metalloproteinase-9 (MMP-9), tissue inhibitor of metalloproteinase-1 (TIMP-1), MMP-9/TIMP-1 complex, C-terminal telopeptide of collagen type 1 (CITP), and endothelin-1 (ET-1) were determined in 27 high-risk IPAH patients and 30 healthy volunteers. Results. OP in IPAH was detected in 50% of the examinees. The serum levels of CITP, MMP-9, TIMP-1, and ET-1 proved to be higher in the high-risk IPAH patients than in the healthy volunteers. There was a direct correlation between BMD and six-minute walk test and an inverse correlation with total pulmonary vascular resistance (TPVR). Serum TMIP-1 levels correlated with cardiac index and TPVR; ET-1 concentrations were directly related to pulmonary artery systolic pressure, cardiac index, and TPVR. Inverse relationships were found between BMD and circulating CITP, MMP-9, TMIP-1, MMP-9/TMIP-1, and ET-1. At the same time, there was only a tendency towards a positive correlation between serum CITP and ET-1 concentrations. Conclusion. The results of the investigation confirm that endothelin system dysregulation plays a leading role in the development of persistent hemodynamic disorders in high-risk IPAH and suggest that it is involved in the development of osteopenic syndrome. Enhanced ET-1 secretion initiates bone loss possibly via activation of connective tissue matrix destruction.</p></abstract><trans-abstract xml:lang="ru"><p>Резюме Цель исследования — определить роль циркулирующих биомаркеров метаболизма коллагена, межклеточного вещества и ремоделирования сосудов в формировании остеопороза (ОП) при идиопатической легочной артериальной гипертонии (ИЛАГ). Материалы и методы. Функционально-гемодинамические параметры, минеральную плотность костной ткани (МПКТ) в поясничном отделе позвоночника (LS) и шейке бедренной кости (FN), уровни металлопротеиназы-9 (ММP-9), ее тканевого ингибитора (TIMP-1) и комплекса ММР-9/ТIМР-1, C-концевого телопептида коллагена I типа (CITP) и эндотелина-1 (ЭТ-1) в сыворотке определяли у 27 пациентов с ИЛАГ высокого риска и 30 здоровых добровольцев. Результаты. ОП при ИЛАГ выявлен у 50% обследованных. Уровни CITP, MMP-9, TIMP-1 и ЭТ-1 в сыворотке крови пациентов с ИЛАГ высокого риска оказались выше, чем у здоровых добровольцев. Обнаружена прямая зависимость между МПКТ и тестом с 6-минутной ходьбой и обратная с общим легочным сосудистым сопротивлением (ОЛСС). Уровень TMIP-1 в сыворотке крови коррелировал с сердечным индексом и ОЛСС; концентрация ЭТ-1 прямо связана с показателями СДЛА, сердечного индекса и ОЛСС. Выявлены обратные связи между МПКТ и циркулирующими СITP, MMP-9, TMIP-1, комплекса MMP-9/TMIP-1 и ЭТ-1. При этом наблюдалась только тенденция к положительной корреляции между концентрацией CITP и уровнем ЭТ-1 в сыворотке крови. Заключение. Результаты исследования подтверждают ведущую роль дизрегуляции эндотелиновой системы в развитии стойких гемодинамических нарушений при ИЛАГ высокого риска и свидетельствуют об ее участии в развитии остеопенического синдрома. Повышенная секреция ЭТ-1 инициирует потерю костной ткани, возможно, через активацию распада соединительнотканного матрикса.</p></trans-abstract><kwd-group xml:lang="en"><kwd>idiopathic pulmonary arterial hypertension</kwd><kwd>osteoporosis</kwd><kwd>endothelin-1</kwd><kwd>matrix metalloproteinase-9</kwd><kwd>tissue inhibitor of metalloproteinase-1</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>идиопатическая легочная артериальная гипертония</kwd><kwd>остеопороз</kwd><kwd>эндотелин-1</kwd><kwd>металлопротеиназа-9</kwd><kwd>тканевой ингибитор металлопротеиназы</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Wang TK, O’Sullivan S, Gamble GD, Ruygrok PN. Bone density in heart or lung transplant recipients — a longitudinal study. Transplant Proc. 2013;45(6):2357-2365. doi:10.1016/j.transproceed.2012.09.117</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Global Initiative for Chronic Obstructive Lung Disease (updated 2016).http://www.goldcopd.org/uploads/users/files/WatermarkedGlobal_20Strategy_202016(1).pdf</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>GINA Report, Global Strategy for Asthma Management and Prevention. http://ginasthma.org/gina-report-global-strategy-for-asthma-management-and-prevention/</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Bon JM, Zhang Y, Duncan SR, Pilewski JM, Zaldonis D, Zeevi A, McCurry KR, Greenspan SL, Sciurba FC. Plasma inflammatory mediators associated with bone metabolism in COPD. COPD. 2010;7:186-191. doi:10.3109/15412555.2010.482114</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Vrieze A, de Greef MH, Wijkstra PJ, Wempe JB. Low bone mineral density in COPD patients related to worse lung function, low weight and decreased fat-free mass. Osteoporos Int. 2007;18(9):1197-1202.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Franco CB, Paz-Filho G, Gomes PE, Nascimento VB, Kulak CA, Boguszewski CL, Borba VZ. Chronic obstructive pulmonary disease is associated with osteoporosis and low levels of vitamin D. Osteoporos Int. 2009;20:1881-1887. doi:10.1007/s00198-009-0890-5</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Katsura H, Kida K. A comparison of bone mineral density in elderly female patients with COPD and bronchial asthma. Chest. 2002;122:1949-1955.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Мартынюк Т.В., Чазова И.Е. Новые возможности в стратегии лечения больных с идиопатической легочной гипертензией: антагонист рецепторов эндотелина бозентан. Системные гипертензии. 2008;4:25-36. http://www.gipertonik.ru/files/journals/SG4(2008).pdf</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67-119. doi:10.1093/eurheartj/ehv317</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Tschopp O, Schmid C, Speich R, Seifert B, Russi EW, Boehler A. Pretransplantation bone disease in patients with primary pulmonary hypertension. Chest. 2006;129:1002-1008.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Malik N, McCarthy K, Minai OA. Prevalence and significance of decreased bone density in pulmonary arterial hypertension. South Med J. 2012;105(7):344-349. doi:10.1097/SMJ.0b013e31825b8117</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Peled N, Shitrit D, Fox BD, Shlomi D, Amital A, Bendayan D, Kramer MR. Peripheral arterial stiffness and endothelial dysfunction in idiopathic and scleroderma associated pulmonary arterial hypertension. J Rheumatol. 2009;36(5):970-975. doi:10.3899/jrheum.081088</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Safdar Z, Tamez E, Frost A, Guffey D, Minard CG, Entman ML. Collagen Metabolism Biomarkers and Health Related Quality of Life in Pulmonary Arterial Hypertension. Int J Cardiovasc Res. 2015;4(2). doi:10.4172/2324-8602.1000198</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Alangiakrishman K, Juby A, Hanley D, Tymchak W, Sclater A. Role of vascular factors in osteoporosis. J Gerontol: Med Scie. 2003;58(4):362-366.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Sumino H, Ichikawa S, Kasama S et al. Relationship between brachial arterial endothelial function and lumbar spine bone mineral density in postmenopausal women. Circulation J. 2007;71(10):1555-1559. doi:10.1253/circj.71.1555</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Prasad M, Reriani M, Khosla S, Gössl M, Lennon R, Gulati R, Prasad A, Lerman LO, Lerman A. Coronary microvascular endothelial dysfunction is an independent predictor of development of osteoporosis in postmenopausal women. Vasc Health Risk Manag. 2014;10:533-538. doi:10.2147/VHRM.S63580</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Delgado-Frías E, López-Mejias R, Genre F, Ubilla B, Gómez Rodríguez-Bethencourt MA, González-Díaz A, de Vera-González AM, González-Rivero AF, Díaz-González F, González-Gay MA, Ferraz-Amaro I. Relationship between endothelial dysfunction and osteoprotegerin, vitamin D, and bone mineral density in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2015;33(2):241-249.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Madonna R, Novo G, Balistreri CR. Cellular and molecular basis of the imbalance between vascular damage and repair in aging and age-related diseases: As biomarkers and targets for new treatments. Mech Ageing Dev. 2016 Mar 15. pii: S0047-6374(16)30026-4. doi:10.1016/j.mad.2016.03.005</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Clarkin CE, Gerstenfeld LC. VEGF and bone cell signalling: an essential vessel for communication? Cell Biochem Funct. 2013;31(1):1-11. doi:10.1002/cbf.2911</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Wang XM, Shi K, Li JJ, Chen TT, Guo YH, Liu YL, Yang YF, Yang S. Effects of angiotensin II intervention on MMP-2, MMP-9, TIMP-1, and collagen expression in rats with pulmonary hypertension. Genet Mol Res. 2015;14(1):1707-1717. doi:10.4238/2015.March.6.17</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Pardo A, Cabrera S, Maldonado M, Selman M. Role of matrix metalloproteinases in the pathogenesis of idiopathic pulmonary fibrosis. Respir Res. 2016;17(1):23. doi:10.1186/s12931-016-0343-6</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Schumann C, Lepper PM, Frank H, Schneiderbauer R, Wibmer T, Kropf C, Stoiber KM, Rüdiger S, Kruska L, Krahn T, Kramer F. Circulating biomarkers of tissue remodelling in pulmonary hypertension. Biomarkers. 2010;15(6):523-532. doi:10.3109/1354750X.2010.492431</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Jiang L, Zhou T, Liu H. Combined effects of the ATP-sensitive potassium channel opener pinacidil and simvastatin on pulmonary vascular remodeling in rats with monocrotaline-induced pulmonary arterial hypertension. Pharmazie. 2012;67(6):547-552.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Невзорова В.А., Тилик Т.В., Гилифанов Е.А., Панченко Е.А., Вахрушева С.Е., Тилик В.В. Роль матриксных металлопротеиназ в формировании морфофункционального дисбаланса воздухоносных путей при хронической обструктивной болезни легких. Тихоокеанский медицинский журнал. 2011;2:9-13. Доступно по: http://www.tmj-vgmu.ru/files/old/PMJ_2009-2011/1509.pdf</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol. 2000;2(10):737-744.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Anderson TL, del Carem Ovejero M, Kirkegaard T et al. A scrutiny of matrix metalloproteinases in osteoclasts: evidence for heterogeneity and for the presence of MMPs synthesized by other cells. Bone. 2004;35:1107-1119.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Li Y, Zhang Zh, Xu Yo et al. TNF-α Up-regulates Matrix Metalloproteinase-9 Expression and Activity in Alveolar Macrophages from Patients with Chronic Obstructive Pulmonary Disease. J Huazhong University of Science and Technology 2006;26(6):647-650. doi:10.1007/s 11596-006-0604-6</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Song H, Cheng Y, Bi G, Zhu Y, Jun W, Ma W, Wu H. Release of Matrix Metalloproteinases-2 and 9 by S-Nitrosylated Caveolin-1 Contributes to Degradation of Extracellular Matrix in tPA-Treated Hypoxic Endothelial Cells. PLoS One. 2016;11(2):e0149269. doi:10.1371/journal.pone.0149269</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Safdar Z, Tamez E, Chan W, Arya B, Ge Y, Deswal A, Bozkurt B, Frost A, Entman M. Circulating collagen biomarkers as indicators of disease severity in pulmonary arterial hypertension. JACC Heart Fail. 2014;2(4):412-421. doi:10.1016/j.jchf.2014.03.013</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Benza RL, Gomberg-Maitland M, Demarco T, Frost AE, Torbicki A, Langleben D, Pulido T, Correa-Jaque P, Passineau MJ, Wiener HW, Tamari M, Hirota T, Kubo M, Tiwari HK. Endothelin-1 Pathway Polymorphisms and Outcomes in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2015;192(11):1345-1354. doi:10.1164/rccm.201501-0196OC</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Serizawa K, Yogo K, Tashiro Y, Takeda S, Kawasaki R, Aizawa K, Endo K. Eldecalcitol prevents endothelial dysfunction in postmenopausal osteoporosis model rats. J Endocrinol. 2016;228(2):75-84. doi:10.1530/JOE-15-0332</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Mestek ML, Weil BR, Greiner JJ, Westby CM, DeSouza CA, Stauffer BL. Osteopenia and endothelin-1-mediated vasconstrictor tone in postmenopausal women. Bone. 2010;47(3):542-545. doi:10.1016/j.bone.2010.05.041</mixed-citation></ref></ref-list></back></article>
